Thu, September 27, 2012
Wed, September 26, 2012
Tue, September 25, 2012
Mon, September 24, 2012
Sun, September 23, 2012
Fri, September 21, 2012
Thu, September 20, 2012
Wed, September 19, 2012
Tue, September 18, 2012
Mon, September 17, 2012
Sun, September 16, 2012
Fri, September 14, 2012
Thu, September 13, 2012
Wed, September 12, 2012
Tue, September 11, 2012

MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference


//health-fitness.news-articles.net/content/2012/ .. e-craig-hallum-2012-alpha-select-conference.html
Published in Health and Fitness on Thursday, September 20th 2012 at 9:16 GMT by Market Wire   Print publication without navigation


MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference -- KENNESAW, Ga., Sept. 20, 2012 /PRNewswire/ --

MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference

KENNESAW, Ga., Sept. 20, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane announced today that it will present at the Craig-Hallum 3rd Annual  Alpha Select Conference in New York City.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Thursday, September 27th, at 3:30 p.m. Eastern Time at the Sentry Centers.  A webcast of this presentation will be available on the Company's website, [ www.mimedx.com ]. 

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 90,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

SOURCE MiMedx, Inc.



[ Back to top ]

RELATED LINKS
[ www.mimedx.com ]


Publication Contributing Sources